Galectin Therapeutics Inc. (GALT)
Company Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration.
The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011.
Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Country | United States |
Founded | 2000 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 12 |
CEO | Joel Lewis |
Contact Details
Address: 4960 Peachtree Industrial Boulevard, Suite 240 Norcross, Georgia 30071 United States | |
Phone | 678-620-3186 |
Website | galectintherapeutics.com |
Stock Details
Ticker Symbol | GALT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001133416 |
CUSIP Number | 363225202 |
ISIN Number | US3632252025 |
Employer ID | 04-3562325 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Joel Lewis | President, Chief Executive Officer and Director |
Jack W. Callicutt CPA | Chief Financial Officer, Treasurer and Corporate Secretary |
Dr. Pol F. Boudes M.D., Ph.D. | Chief Medical Officer |
Robert Tritt | General Counsel |
Jeff Katstra | Head of CMC and Pharmaceutical Development |
Beth Knowles | Executive Assistant and Officer Manager |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 11, 2023 | 8-K | Current Report |
Dec 7, 2023 | 8-K | Current Report |
Dec 1, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Nov 13, 2023 | 8-K/A | [Amend] Current report |
Nov 13, 2023 | 8-K | Current Report |
Nov 13, 2023 | 10-Q | Quarterly Report |
Oct 6, 2023 | ARS | Filing |
Oct 6, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Oct 6, 2023 | DEF 14A | Other definitive proxy statements |
Sep 11, 2023 | 144 | Filing |